Core Viewpoint - Verrica Pharmaceuticals Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $42 million before expenses [2][4]. Group 1: Offering Details - The company is offering 44,964,045 shares of common stock and pre-funded warrants for 2,235,955 shares, along with Series A and Series B warrants for 23,600,000 shares each at exercise prices of $1.0680 and $1.3350 respectively [1]. - The combined public offering price is set at $0.89 per share of common stock and accompanying warrants, or $0.8899 per pre-funded warrant [1]. - The offering is expected to close on November 22, 2024, subject to customary closing conditions [1]. Group 2: Underwriter Information - Jefferies is acting as the sole book-running manager for the offering [3]. Group 3: Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its product YCANTH® (VP-102) being the first FDA-approved treatment for molluscum contagiosum [6]. - The company is also developing VP-103 for plantar warts and has a license agreement with Lytix Biopharma AS for VP-315 targeting non-melanoma skin cancers [6].

WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value VRCA The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance -  WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of two abstracts that will be presented as posters at the Fall ...

- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to ...

NEW ORLEANS, Sept. 27, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA). In December 2020, the Company submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for regulatory approval of its lead product, VP-102 or YCANTH, for the treatment of molluscum contagiosum, a skin disease. ...

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 27.91%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.38, delivering a surprise of 29.63%. Over the last four quarters, the compa ...

- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug ...

VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is expected to co ...

WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 tri ...